Cargando…

Varicella-zoster virus Neurovasculitis (VZV-NV) in the Setting of Autoantibodies to Interferon alpha (anti-IFNα)

BACKGROUND: VZV-NV resulting in CNS damage is rare in immunocompetent hosts. Humoral immunity protects against acquiring VZV, and T-cell mediated immunity shields against reactivation of the latent virus. Individuals who are immunocompromised due to T-cell mediated defects can present with systemic ...

Descripción completa

Detalles Bibliográficos
Autores principales: Ansari, Rahila, Zerbe, Christa, Lisco, Andrea, Rosen, Lindsey, Holland, Steven, Bonomo, Robert A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632258/
http://dx.doi.org/10.1093/ofid/ofx163.716
_version_ 1783269664175947776
author Ansari, Rahila
Zerbe, Christa
Lisco, Andrea
Rosen, Lindsey
Holland, Steven
Bonomo, Robert A
author_facet Ansari, Rahila
Zerbe, Christa
Lisco, Andrea
Rosen, Lindsey
Holland, Steven
Bonomo, Robert A
author_sort Ansari, Rahila
collection PubMed
description BACKGROUND: VZV-NV resulting in CNS damage is rare in immunocompetent hosts. Humoral immunity protects against acquiring VZV, and T-cell mediated immunity shields against reactivation of the latent virus. Individuals who are immunocompromised due to T-cell mediated defects can present with systemic VZV. METHODS: Case report of a previously healthy man who developed VZV-NV associated with autoantibodies to IFNα. RESULTS: A previously healthy 64 year-old man developed an acute T3 Brown-Sequard syndrome. Symptoms progressed to include bilateral lower extremity weakness, ptosis, ophthalmoplegia, and encephalopathy. Magnetic resonance imaging (MRI) showed diffuse T2 hyperintensities with enhancement throughout the spine and brain, including enhancement of his meninges, roots, and cranial nerves. Successive cerebrospinal fluid (CSF) studies revealed increasing B-cell lymphocytosis, (maximum 661 cells/mcl), and CSF protein (maximum 242 mg/dL). CSF PCR was positive for VZV and IgM antibodies. Further testing showed anti-IFNα autoantibodies in the plasma and CSF. Serum anti-IFNα fluorescence intensity was 30 times normal, and his plasma blocked IFNα-induced STAT-1 phosphorylation in normal monocytes. Treatment with acyclovir and methylprednisolone resulted in improvement. Repeat LP following treatment revealed 32 WBC/mcl with normal protein. Follow-up MRI did not show any new lesions. Three years after initial presentation, he continues to be stable without clinical relapses, or subclinical changes on MRI. Serum studies were positive for VZV IgG and negative for IgM. CSF PCR was positive for VZV. Lastly, serum anti-IFNα fluorescence intensity remained 25 times normal, and his plasma continued to block IFNα-induced STAT-1 phosphorylation in normal monocytes. CONCLUSION: This is the first identified case of CNS VZV-NV in the setting of binding and blocking autoantibodies to IFNα in the serum and CSF. Elevated serum and CSF levels of anti-INFα may impair natural killer, T-cell and neuronal antiviral activity. Disruption of T-cell mediated immunity due to anti-IFNα could cause an adult-onset immunocompromised state with severe VZV reactivation. The association of high-titer neutralizing autoantibodies to INFα in an adult with CNS VZV is novel and may be clinically relevant. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-5632258
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-56322582017-10-12 Varicella-zoster virus Neurovasculitis (VZV-NV) in the Setting of Autoantibodies to Interferon alpha (anti-IFNα) Ansari, Rahila Zerbe, Christa Lisco, Andrea Rosen, Lindsey Holland, Steven Bonomo, Robert A Open Forum Infect Dis Abstracts BACKGROUND: VZV-NV resulting in CNS damage is rare in immunocompetent hosts. Humoral immunity protects against acquiring VZV, and T-cell mediated immunity shields against reactivation of the latent virus. Individuals who are immunocompromised due to T-cell mediated defects can present with systemic VZV. METHODS: Case report of a previously healthy man who developed VZV-NV associated with autoantibodies to IFNα. RESULTS: A previously healthy 64 year-old man developed an acute T3 Brown-Sequard syndrome. Symptoms progressed to include bilateral lower extremity weakness, ptosis, ophthalmoplegia, and encephalopathy. Magnetic resonance imaging (MRI) showed diffuse T2 hyperintensities with enhancement throughout the spine and brain, including enhancement of his meninges, roots, and cranial nerves. Successive cerebrospinal fluid (CSF) studies revealed increasing B-cell lymphocytosis, (maximum 661 cells/mcl), and CSF protein (maximum 242 mg/dL). CSF PCR was positive for VZV and IgM antibodies. Further testing showed anti-IFNα autoantibodies in the plasma and CSF. Serum anti-IFNα fluorescence intensity was 30 times normal, and his plasma blocked IFNα-induced STAT-1 phosphorylation in normal monocytes. Treatment with acyclovir and methylprednisolone resulted in improvement. Repeat LP following treatment revealed 32 WBC/mcl with normal protein. Follow-up MRI did not show any new lesions. Three years after initial presentation, he continues to be stable without clinical relapses, or subclinical changes on MRI. Serum studies were positive for VZV IgG and negative for IgM. CSF PCR was positive for VZV. Lastly, serum anti-IFNα fluorescence intensity remained 25 times normal, and his plasma continued to block IFNα-induced STAT-1 phosphorylation in normal monocytes. CONCLUSION: This is the first identified case of CNS VZV-NV in the setting of binding and blocking autoantibodies to IFNα in the serum and CSF. Elevated serum and CSF levels of anti-INFα may impair natural killer, T-cell and neuronal antiviral activity. Disruption of T-cell mediated immunity due to anti-IFNα could cause an adult-onset immunocompromised state with severe VZV reactivation. The association of high-titer neutralizing autoantibodies to INFα in an adult with CNS VZV is novel and may be clinically relevant. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2017-10-04 /pmc/articles/PMC5632258/ http://dx.doi.org/10.1093/ofid/ofx163.716 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Ansari, Rahila
Zerbe, Christa
Lisco, Andrea
Rosen, Lindsey
Holland, Steven
Bonomo, Robert A
Varicella-zoster virus Neurovasculitis (VZV-NV) in the Setting of Autoantibodies to Interferon alpha (anti-IFNα)
title Varicella-zoster virus Neurovasculitis (VZV-NV) in the Setting of Autoantibodies to Interferon alpha (anti-IFNα)
title_full Varicella-zoster virus Neurovasculitis (VZV-NV) in the Setting of Autoantibodies to Interferon alpha (anti-IFNα)
title_fullStr Varicella-zoster virus Neurovasculitis (VZV-NV) in the Setting of Autoantibodies to Interferon alpha (anti-IFNα)
title_full_unstemmed Varicella-zoster virus Neurovasculitis (VZV-NV) in the Setting of Autoantibodies to Interferon alpha (anti-IFNα)
title_short Varicella-zoster virus Neurovasculitis (VZV-NV) in the Setting of Autoantibodies to Interferon alpha (anti-IFNα)
title_sort varicella-zoster virus neurovasculitis (vzv-nv) in the setting of autoantibodies to interferon alpha (anti-ifnα)
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632258/
http://dx.doi.org/10.1093/ofid/ofx163.716
work_keys_str_mv AT ansarirahila varicellazostervirusneurovasculitisvzvnvinthesettingofautoantibodiestointerferonalphaantiifna
AT zerbechrista varicellazostervirusneurovasculitisvzvnvinthesettingofautoantibodiestointerferonalphaantiifna
AT liscoandrea varicellazostervirusneurovasculitisvzvnvinthesettingofautoantibodiestointerferonalphaantiifna
AT rosenlindsey varicellazostervirusneurovasculitisvzvnvinthesettingofautoantibodiestointerferonalphaantiifna
AT hollandsteven varicellazostervirusneurovasculitisvzvnvinthesettingofautoantibodiestointerferonalphaantiifna
AT bonomoroberta varicellazostervirusneurovasculitisvzvnvinthesettingofautoantibodiestointerferonalphaantiifna